Cooper Companies Completes Strategic Review

Cooper Companies’ announcement that it completed a strategic review and has increased its share buyback is a direct move toward returning capital to shareholders, a priority cited by management for FY2026. The company’s FY2025 financial position provides context for that decision: revenue was $4.09 billion (up 5% year-over-year), GAAP gross margin was 66% (non-GAAP 68%), GAAP operating margin 17% (non-GAAP 26%), and net income was $374.9 million. Cash from operations for FY2025 was $796.1 million, a material cash flow figure that can support balance-sheet flexibility and capital-return actions such as buybacks.

FY2025 metrics show improved non-GAAP margins (+100 basis points year-over-year for both gross and operating margin) and strong operating cash generation, which helps explain management’s ability to expand repurchases without needing to rely on external financing. The company operates two segments—CooperVision (contact lenses) and CooperSurgical (fertility and women’s health)—and continues to invest in growth areas such as myopia management lenses, distribution/packaging improvements, and integrated fertility solutions. Investors should note limitations in the disclosure: the announcement indicates an increase to the buyback program but does not provide the authorization size, timing, or funding breakdown. The company’s filings also emphasize risks that can affect future performance—supply-chain concentration for silicone hydrogel components, regulatory approvals, cybersecurity, acquisition integration, and customer consolidation—which remain relevant when assessing the durability of cash flows that underwrite buybacks.